Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of...
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 31 décembre 2023
04 janv. 2024 11h45 HE
|
Transgene S.A.
Strasbourg, le 4 janvier 2024 – 17h45 Au titre du contrat de liquidité confié par Transgene à Natixis Oddo BHF SCA, à la date du 31 décembre 2023, les moyens suivants figuraient au compte de...
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023
04 janv. 2024 11h45 HE
|
Transgene S.A.
Strasbourg, January 4, 2024 – 05:45 pm CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2023, the following resources were managed through the...